Cybin Inc. Common Stock (HELP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cybin Inc. Common Stock (HELP) has a cash flow conversion efficiency ratio of -0.117x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.84 Million) by net assets ($375.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cybin Inc. Common Stock (HELP) total market value for the company's overall valuation and market capitalisation.
Cybin Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cybin Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cybin Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cybin Inc. Common Stock ranked by their cash flow conversion efficiency. See Cybin Inc. Common Stock cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOCL Corporation Limited
NSE:GOCLCORP
|
-0.008x |
|
Tian Zheng International Precision Machinery Co Ltd
TWO:6654
|
-0.065x |
|
Decora SA
WAR:DCR
|
0.032x |
|
Metals Acquisition Corp. II
NYSE:MTAL
|
-0.001x |
|
Omaxe Limited
NSE:OMAXE
|
0.064x |
|
Celon Pharma SA
WAR:CLN
|
-0.009x |
|
Sovereign Metals Ltd
AU:SVM
|
-0.301x |
|
Hold-Key Electric Wire & Cable Co Ltd
TW:1618
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Cybin Inc. Common Stock (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cybin Inc. Common Stock from 2017 to 2025. View latest Cybin Inc. Common Stock stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $237.20 Million | $-101.30 Million | -0.427x | -80.93% |
| 2024-03-31 | $291.93 Million | $-68.91 Million | -0.236x | +76.00% |
| 2023-03-31 | $48.23 Million | $-47.43 Million | -0.983x | -65.65% |
| 2022-03-31 | $76.16 Million | $-45.21 Million | -0.594x | -168.68% |
| 2021-03-31 | $86.12 Million | $-19.03 Million | -0.221x | -23002.44% |
| 2020-03-31 | $1.45 Million | $-1.38K | -0.001x | +99.55% |
| 2019-03-31 | $394.73K | $-83.78K | -0.212x | +60.57% |
| 2018-03-31 | $440.25K | $-237.03K | -0.538x | -5701.70% |
| 2017-03-31 | $292.78K | $2.81K | 0.010x | -- |
About Cybin Inc. Common Stock
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical tr… Read more